Stock ALRN AILERON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aileron Therapeutics, Inc.

Equities

ALRN

US00887A2042

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
5 USD +1.42% Intraday chart for Aileron Therapeutics, Inc. 0.00% +64.01%
Apr. 18 Ladenburg Thalmann Adjusts Aileron Therapeutics Price Target to $19 From $9, Maintains Buy Rating MT
Apr. 15 Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ladenburg Thalmann Adjusts Aileron Therapeutics Price Target to $19 From $9, Maintains Buy Rating
MT
Aileron Therapeutics : Corporate Presentation April 2024
PU
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Aileron Therapeutics : Management Change/Compensation - Form 8-K
PU
Aileron Therapeutics, Inc. Announces CFO Changes
CI
Aileron Therapeutics, Inc. Announces Board Changes
CI
Aileron Therapeutics Names Brian Windsor as CEO
MT
Aileron Therapeutics Announces CEO Transition
AQ
Aileron Therapeutics, Inc. Announces Appointment of Brian Windsor as President and to the Board of Directors
CI
Aileron Therapeutics, Inc. Announces CEO Changes
CI
Aileron Therapeutics, Inc. Announces Resignation of Nolan Sigal, M.D., Ph.D. from Board of Directors, Member of Nominating and Corporate Governance Committee
CI
Transcript : Aileron Therapeutics, Inc. - Special Call
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
AQ
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
AQ
North American Morning Briefing : Stock Futures, -2-
DJ
Ladenburg Thalmann Upgrades Aileron Therapeutics to Buy From Neutral, Price Target is $9
MT
Transcript : Aileron Therapeutics, Inc., Lung Therapeutics, Inc. - M&A Call
Aileron Therapeutics Acquires Lung Therapeutics in Stock-for-Stock Deal
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALRN Stock
  4. News Aileron Therapeutics, Inc.